Xencor Inc (XNCR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Xencor Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 19.40 $ — 86% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 4.1%
- Exp. sales growth 3Y > 5% -3.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -3.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 3
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -14.7%
- ROCE > 15% -22.8%
- Expected return > 10% -12.6%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -8.6% failed
- More than 10% revenue growth is expected for the coming year 51.2% passed
- Share count grows by less than 3% a year 7.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -96.5% failed
- Gross margin at 40% or higher and without meaningful erosion 91.6% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 360 m net cash passed
- Operating cash flow covers the profits of the last three years 198 m failed
- Return on capital at 15% or higher, or up versus two years ago -22.8% failed
- Insiders hold at least 10% or are net buyers 1.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 46.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -4.03 | -5.04 – -3.36 | 77 | -224.7% | 12 |
| 12/31/2027 | -3.55 | -4.76 – -2.20 | 117 | 11.9% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.84 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.73 | – | 70 | 37.40 | -76.40 | -56 | -58 |
| 2025: Q1 | -0.66 | – | 33 | 104.60 | -147.90 | -16 | -18 |
| 2025: Q2 | -0.41 | – | 44 | 157.10 | -70.70 | -36 | -37 |
| 2025: Q3 | -0.08 | – | 21 | 18.00 | -28.70 | -31 | -31 |
| 2025: Q4 | -0.09 | – | 28 | -59.70 | -23.60 | -52 | -53 |
| 2026: Q1 | -1.71 | – | 5 | -86.20 | -2,854.70 | -68 | -68 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 88 | 23 | 24 | 0.56 | 95 | 314 | 429 |
| 2017 | 36 | -54 | -49 | -1.05 | -34 | 282 | 390 |
| 2018 | 41 | -79 | -70 | -1.31 | -80 | 522 | 577 |
| 2019 | 157 | 14 | 27 | 0.46 | 64 | 593 | 670 |
| 2020 | 123 | -77 | -64 | -1.11 | -5 | 572 | 703 |
| 2021 | 275 | 44 | 83 | 1.37 | -17 | 734 | 838 |
| 2022 | 165 | -82 | -55 | -0.93 | 24 | 728 | 846 |
| 2023 | 168 | -139 | -126 | -2.08 | 85 | 669 | 953 |
| 2024 | 110 | -178 | -233 | -3.58 | -202 | 678 | 952 |
| 2025 | 126 | -178 | -92 | -1.24 | -135 | 636 | 876 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Xencor, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entdeckung und Entwicklung technisch entwickelter Antikörper zur Behandlung von Krebs und Autoimmunerkrankungen.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 260 |
| Headquarters | Pasadena, CA |
| Address | 465 North Halstead Street, 91107 Pasadena, United States |
| Phone | 626 305 5900 |
| Website | xencor.com |
| IPO Date | 3. Dec 2013 |
| ISIN | US98401F1057 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, President & Director | 1970 |
| Bart Jan Cornelissen | Senior VP & CFO | 1978 |
| John R. Desjarlais Ph.D. | Executive VP of Research & Chief Scientific Officer | 1964 |
| Celia E. Eckert J.D. | Senior VP, General Counsel & Corporate Secretary | 1972 |
| Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations | – |
| Jennifer Sandoz | Senior VIce President of Human Resources | – |
| Kirk Rosemark RAC | Senior Vice President of Regulatory Affairs & Quality Assurance | 1965 |
| Eric P. Kowack | Senior Vice President of Program Leadership & Alliance Management | – |
| Dane Vincent Leone C.F.A. | Executive VP & Chief Strategy Officer | – |
| Mark Osterman M.D. | Senior Vice President of Clinical Development (Autoimmune) | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 16. Jun 2026 | Deshaies Raymond Joseph | Director | Other | 10,302 | 0.00 | – |
| 16. Jun 2026 | Feigal Ellen | Director | Other | 10,302 | 0.00 | – |
| 16. Jun 2026 | Klencke Barbara | Director | Other | 10,302 | 0.00 | – |
| 16. Jun 2026 | Gustafson Kurt A | Director | Other | 10,302 | 0.00 | – |
| 16. Jun 2026 | Montgomery Alan Bruce | Director | Other | 10,302 | 0.00 | – |
| 16. Jun 2026 | Ranieri Richard J | Director | Other | 10,302 | 0.00 | – |
| 16. Jun 2026 | Simpson Todd E | Director | Other | 10,302 | 0.00 | – |
| 16. Jun 2026 | Gorman Kevin Charles | Director | Other | 10,302 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.